Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Cash (2024 - 2025)

Historic Change in Cash for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$17.8 million.

  • Xilio Therapeutics' Change in Cash fell 2993.28% to -$17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year change of. This contributed to the annual value of $10.8 million for FY2024, which is 11425.13% up from last year.
  • Per Xilio Therapeutics' latest filing, its Change in Cash stood at -$17.8 million for Q3 2025, which was down 2993.28% from $32.5 million recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Change in Cash high stood at $40.0 million for Q2 2024, and its period low was -$17.8 million during Q3 2025.